Merck: A Buy For 2026, But The Clock Is Still Ticking (NYSE:MRK)

Core Viewpoint - Investors have been discounting Merck due to the anticipated loss of exclusivity for Keytruda in 2028, but there may be overlooked bullish signals in the recent earnings report despite softer-than-expected guidance [1] Group 1: Company Overview - Merck's Keytruda is facing a loss of exclusivity in 2028, which has been a significant concern for investors [1] - The recent earnings report highlighted softer-than-expected guidance, which may have contributed to negative sentiment among investors [1] Group 2: Analyst Background - The article references an analyst with a strong background in pharmaceuticals and biotechnology, including a Ph.D. from Stanford and experience at major companies like Merck [1]